Grace Therapeutics (NASDAQ:GRCE) Posts Earnings Results

Grace Therapeutics (NASDAQ:GRCE) released its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports.

Grace Therapeutics Price Performance

Grace Therapeutics stock opened at $3.45 on Friday. Grace Therapeutics has a 1-year low of $2.13 and a 1-year high of $4.97. The company has a market capitalization of $34.98 million, a price-to-earnings ratio of -3.42 and a beta of 1.36. The firm has a fifty day simple moving average of $3.70.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.